SUMMARY Twenty-three children (aged less than 18 years) and 17 adults with severe widespread dystonia were treated with high doses of benzhexol (up to 130 mg daily introduced slowly over many weeks). Children tolerated higher doses (median 30 mg/day) than adults (median 20 mg/ day). 52% of the children gained useful benefit, many (43%) without unwanted side effects. Such an approach was less successful in adults; 41% gained benefit, but only 35% had no side effects. Twelve adults with severe axial dystonia, and two children with life-threatening generalised dystonia were treated with a combination of a low constant dose of tetrabenazine to which were added pimozide and benzhexol as necessary. The dose of tetrabenazine was aimed at 75 mg daily; pimozide was increased (6 to 25 mg/day) until the dystonia was relieved or Parkinsonism and other side-effects prevented further increments; if necessary benzhexol (6 to 30 mg/day) then was added to control side-effects and to provide additional benefit.
The treatment of the syndrome of torsion dystonia is very difficult. The problem is that patients with this disorder do not show any consistent pharmacological response to the many different categories of drugs that have been tried.' A minority of patients have benefited from carbamazepine, levodopa or dopamine antagonists, anticholinergic drugs or benzodiazepines, but it has proved impossible to predict which patients will be helped by which drugs, and many are not helped at all by conventional drug therapy.
Over the years, we have gradually evolved a plan for management of patients with severe torsion dystonia, and the results of this approach are the subject of the present report.
In 1979, Fahn and Marsden instituted a doubleblind placebo control trial of benzhexol (trihexi-phenidyl) (Artane), up to 30 mg daily in severe dystonia. The results (to be published elsewhere) were encouraging and Fahn had suggested increasing the dose further to see how much more benefit could be obtained. Fahn's results with high dose benzhexol2 have been published, and we report here our own parallel studies with this approach to the treatment of severe dystonia. Both Fahn' s and our own experience have suggested that adults tolerate anticholinergic less well than children, and achieve less benefit. For this reason, one of us (CDM) has devised a combination drug regime from the management of severely disabling axial dystonia in adults, the results of which also are reported.
The treatment of severe dystonia in children and adults the head and neck, the trunk, each arm and each leg. Segmental refers to dystonia affecting two or more adjacent focal areas but sparing the legs, hemi-dystonia affects the arm and leg on the same side, multifocal refers to dystonia affecting two or more separate focal areas, and generalised refers to widespread dystonia involving the legs and other areas.)
Benzhexol was started in a dose of 2 to 2 5 mg once or twice daily, and increased thereafter by increments of 2 to 2 5 mg per day at weekly intervals until either the dystonia was controlled adequately, or side effects appeared. If side affects were disabling, the dose was reduced till they remitted, and was held at that level for a month or so, before attempting to increase the dose further. Not every patient has yet reached the maximum tolerable dose, and the upper limit reached so far (130 mg/day) may yet be exceeded.
In the early stages a few patients were treated with orphenadrine rather than benzhexol (three children and two adults). For Combined treatment in children Following our experience with the use of combined tetrabenazine, pimozide and benzhexol therapy in adults, we have empolyed the same strategy to treat two children with desperate dystonia. One, a 12-year-old boy, with onset of sporadic idiopathic progressive generalised dystonia at 5 years, was referred under sedation because of such severe dystonic spasms that he had become exhausted with signs of incipient cardiac failure and gastric bleeding. He required paralysis and artificial ventilation, and eventually a tracheostomy, for 2 weeks, while combined treatment was instituted. The other child, a 15-year-old boy with onset of sporadic idiopathic progressive generalised dystonia at 7 years, was bed-bound, anarthric and dysphagic, and in considerable pain due to severe dystonic spasms.
Results
High dose benzhexol treatment in children (table 2) Eleven of the 23 children (52%) gained definite Marsden, Marion, Quinn (2+) , considerable (3+) or dramatic (4+) benefit from this treatment. One 17-year-old girl chairbound because of apparently fixed dystonia of both legs returned to normal walking (4+ benefit) on 78 mg benzhexol daily. One 17-year-old boy dysarthric and unable to swallow without pushing the food down his throat, and with a disabling dystonic writers' cramp, regained intelligible speech and nearly normal swallowing and writing (3+ benefit) on 65 mg benzhexol daily. A 17-year-old boy with torticollis and severe arm dystonia returned to competitive cricket and squash (3+ benefit) on 45 mg benzhexol daily. An 18-year-old boy unable to read or write because of torticollis and graphospasm returned to normal college activities (3+ benefit) on 30 mg daily. One 15-year-old boy severely disabled by generalised dystonia returned to normal schooling.
Improvement was independent of age of onset (0 to 1+ benefit, mean 7-1 years; 2+ to 4+ benefit, mean 8-3 years), age at starting therapy (0 to 1+, mean 1 1-4 years, 2+ to 4+, mean 13-7 years), severity of dystonia at start of therapy (0 to 1+, 7 of 14 with moderate and four of nine with severe disability), or aetiological diagnosis. Seven of 13 with sporadic idiopathic (primary) dystonia, three of five with familial idiopathic (primary) dystonia, and two of five with symptomatic (secondary) dystonia showed definite to dramatic (2+ to 4+) improvement. None of these factors distinguished between those with considerable or dramatic benefit (3+ or 4+), and those with lesser degrees of benefit (0 to 2+). None of the three children who had had previous stereotaxic surgery showed any benefit. Improvement appeared after some weeks or months of treatment. The extent of improvement The treatment of severe dystonia in children and adults To start with a relatively high dose was employed; five patients took 125 to 150 mg daily, while seven patients took 75 to 100 mg daily. Unfortunately it was soon learnt that high doses of tetrabenazine were associated with an unacceptable prevalence of depression. Three patients had to stop the drug because of this side effect and two others had to reduce the dose. At the time of their depression these five patients were taking a mean of 130 mg of tetrabenazine daily. Of the nine patients who continued on tetrabenazine, after dosage adjustment, their mean dose was 90 mg/day, which they have continued for between 1 to 144 months (mean 22).
Six of these 9 patients were taking 75 mg/day or less.
Pimozide then was added to tetrabenazine, in optimum dosage, in seven cases. The initial dose usually was 2 mg mane increasing thereafter by 2 mg at approximately weekly intervals, until side effects occurred or adequate therapeutic response was achieved. The final mean dose of pimozide used in 1170 these seven patients was 11 mg/day (range 6 to 25 mg), as a single morning dose, which they have continued for between 1 to 36 months (mean 12) .
Anticholinergic drugs were added to combined tetrabenazine/pimozide treatment in six patients, or to tetrabenazine alone in four other patients. Benzhexol was used in 10 of these patients, and orphenadrine in the remaining case. As with pimozide, benzhexol was added in a small dose and gradually increased every three to five days. The final mean dose of benzhexol achieved in these patients was 16 mg/day (range 6 to 30 mg), which they have continued for between 1 to 144 months (mean 31-5).
One patient, intolerant of tetrabenazine, was managed on chlorpromazine alone (750 mg daily), which he has continued for 132 months.
On their final optimal regime, two of the patients showed a dramatic improvement (4+) in their dystonia, four showed a marked improvement (3+), three showed a moderate improvement (2+), one showed a slight improvement (1 +), and two showed no improvement (0). The nine patients (75%) showing moderate to dramatic improvement have continued on their drug therapy. Three patients showing slight or no improvement have stopped taking this form of treatment. Those who failed to respond included one patient with tardive dystonia, but another patient with tardive dystonia showed a moderate improvement. Another patient managed on tetrabenazine and benzhexol without pimozide, showed no improvement, and her drugs were stopped because of severe depression and the emergence of extrapyramidal side effects. A further patient with idiopathic (primary) dystonia, who has had previous bilateral stereotaxic surgery, showed only slight improvement, and could not tolerate the combination because of blurred vision and urinary difficulties, as well as Parkinsonism. The other patient who had had previous bilateral stereotaxic surgery showed moderate improvement, but still exhibited obvious dystonia (2+).
Amongst those nine patients who continued on treatment, five were taking combined tetrabenazine, pimozide and benzhexol, two were taking tetrabenazine and benzhexol, one was taking tetrabenazine and pimozide, and one was taking chlorpromazine alone. Amongst these nine patients, three had evident Parkinsonism, but of a severity insufficient to cause disability; one complained of akathisia, two had anticholinergic side effects, and one exhibited some drowsiness. None of these side effects were sufficient to warrant discontinuation of treatment.
The response to treatment in many of these nine patients has been remarkable. Seven of the nine Marsden, Marion, Quinn were bed or chair-bound, with severe and often painful spasms of axial muscles. The remaining two patients could not sit comfortably because of similar axial dystonia. Eight of the nine patients now on treatment can walk and sit comfortably. The remaining patient has shown less improvement, but he is the individual suffering from symptomatic postencephalitic dsytonia.
Combined (tetrabenazine, pimozide and benzhexol) treatment of life-threatening dystonia in children
The first 12-year-old child, paralysed and ventilated to relieve devastating generalised idiopathic dystonia, was started on tetrabenazine (75 mg daily), with increasing pimozide (up to 12 mg daily), to which increasing benzhexol was added after a fortnight. After 2 weeks on this treatment, having reached 12 mg daily of benzhexol, ventilation could be discountinued, and the tracheostomy was closed. After a further two weeks during which the benzhexol was increased to 18 mg daily, he was able to walk home, albeit still with obvious generalised dystonia.
The other severely affected 15-year-old boy was treated with tetrabenazine (75 mg daily), and benzhexol (30 mg daily), but the addition of pimozide (1 mg daily) provoked a super-added acute dystonic reaction, so pimozide was discontinued. Subsequent treatment with tetrabenazine and benzhexol was of no value, so the drugs were withdrawn. He remained severely disabled and bed-bound.
Discussion
High dose benzhexol treatment in children and adults The results of the present study are in broad agreement with those reported by Fahn2 (table 4) . Combining the two studies, 26 of 46 (56%) children, aged less than 18 years at the start of therapy, gained significant benefit from benzhexol therapy. This was of moderate degree, with residual disabling dystonia, in 12 of 46; considerable, but dystonia still evident in nine of 46; and dramatic, with no obvious residual dystonia, in five of 46.
Children could tolerate high doese of benzhexol, up to 80 mg/day in Fahn's study,2 and up to 78 mg/ day in the present investigation, with a suprisingly low incidence of dose-limiting side effects, provided dosage escalation was undertaken very slowly. Despite concern over the effects of such high doses of benzhexol on learning and other higher mental functions, schooling appears to have proceeded normally in our children once optimum dosage had been established. Nevertheless, this remains a cause of concern, and all the children are being monitored for possible adverse effects of high dose benzhexol group.bmj.com on June 19, 2017 -Published by http://jnnp.bmj.com/ Downloaded from
The treatment of severe dystonia in children and adults Fahn.2 Combined therapy for severe disabling adult dystonia Because of the relative lack of success of anticholinergic therapy in adults with dystonia, we have employed combined tetrabenazine, pimozide and anticholinergic treatment in the severely disabled. We have used this approach particularly in those with severe axial dystonia, which commonly prevents sitting, walking and even sleeping. The results of this treatment have been encouraging. Threequarters of those managed in this way have responded to the extent of gaining independent comfortable mobility. The problem of intolerable side effects has been reduced, although not eliminated, by keeping the dose of tetrabenazine low. In another study of 35 patients with dystonia treated with tetrabenazine (mean dose 104 mg/day; range 25-200), 11 were unable to tolerate the drug, and some 80% reported undesirable side effects.'2 Particularly troublesome were drowsiness, akathisia and depression. Nine patients benefited from the drug, but only two showed marked improvement. Jankovic'3 recently reported more favourable results with tetrabenazine in dystonia, as had Swash et al, 4 previously, but many of the patients in these studies experienced similar side effects.
The frequency and severity of the side effects of tetrabenazine may reflect its ability to deplete all three monoamine neurotransmitters (dopamine, noradrenaline and serotonin) and its effects on other neurotransmitters such as acetylcholine and certain amino acids.'5 For this reason, we decreased the dose, aiming to give no more than 75 mg daily, and added a selective post-synaptic dopamine receptor antagonist, pimozide. Pimozide is a potent dopamine antagonist with little effect on other neurotransmitter receptors, as judged by ligand binding studies (unpublished observations). Tetrabenazine recently has also been shown to have post-synaptic antagonist action on dopamine receptors,'6 but this is weak; it inhibits 3H-spiperone binding to striatal homogenates in micromolar contractions, whereas pimozide is effective in the nanomolar range. The combination of tetrabenazine and pimozide may be expected to effectively reduce dopaminergic action in the brain, by a combination of pre-synaptic action by depletion of dopamine stores and post-synaptic receptor blockade. Fog and Pakkenberg'7 have shown that the combination is effective in controlling chorea in Huntington's disease. Our present studies indicate that it also can be of benefit in severe axial dystonia in adults and occasionally in disastrous generalised dystonia in children. However, frequently the doses of tetraMarsden, Marion, Quinn benazine and pimozide required to control dystonia cause disabling Parkinsonism. For this reason, we often added the anticholinergic, benzhexol, which also benefits the dystonia. The art of this method of treatment is to titrate the pimozide and benzhexol, against the low fixed dose of tetrabenazine, to achieve the greatest relief of dystonia with the least Parkinsonism.
Combined tetrabenazine, pimozide and benzhexol therapy can be employed in children, but there are arguments against this line of treatment. Chronic dopamine antagonist therapy can produce disabling tardive disorders, including tardive dystonia.6 It seems unwise to use this therapy in children with dystonia, who face a lifetime of drug treatment. For this reason we prefer high dose anticholinergic therapy as the first line of treatment for childhood dystonia, and for adults with moderately disabling dystonia, reserving combined treatment for those disastrously affected by the illness.
